These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 22470109

  • 1. 17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal cancer growth by inhibiting the expression of heat shock factor-1.
    Sato A, Asano T, Ito K, Asano T.
    Int J Oncol; 2012 Jul; 41(1):46-52. PubMed ID: 22470109
    [Abstract] [Full Text] [Related]

  • 2. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 3. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC, Chen HJ, Huang YC, Tseng SC, Weng SH, Wo TY, Huang YJ, Chiu HC, Tsai MS, Chiou RY, Lin YW.
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [Abstract] [Full Text] [Related]

  • 4. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM, Gillis JL, Hanson AR, Jindal S, Taylor RA, Risbridger GP, Sutherland PD, Scher HI, Raj GV, Knudsen KE, Yeadon T, Australian Prostate Cancer BioResource, Tilley WD, Butler LM.
    Clin Cancer Res; 2012 Jul 01; 18(13):3562-70. PubMed ID: 22573351
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A.
    Exp Hematol; 2006 Dec 01; 34(12):1670-9. PubMed ID: 17157164
    [Abstract] [Full Text] [Related]

  • 7. Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
    Liu H, Zhang T, Chen R, McConkey DJ, Ward JF, Curley SA.
    J Surg Res; 2012 Jul 01; 176(1):147-53. PubMed ID: 22099584
    [Abstract] [Full Text] [Related]

  • 8. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W, Rao Q, Wang M, Tian Z, Lin D, Liu X, Wang J.
    Leuk Res; 2006 May 01; 30(5):575-82. PubMed ID: 16213582
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 11. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM.
    Clin Cancer Res; 2006 Nov 15; 12(22):6826-35. PubMed ID: 17121904
    [Abstract] [Full Text] [Related]

  • 12. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
    Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y.
    Cell Biol Int; 2012 Oct 01; 36(10):893-9. PubMed ID: 22694478
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
    Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R, Narendran A.
    J Exp Ther Oncol; 2008 Oct 01; 7(3):183-93. PubMed ID: 19066127
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M, Yu C, Dai Y, Reese E, Ahmed W, Dent P, Grant S.
    Cancer Res; 2003 Dec 01; 63(23):8420-7. PubMed ID: 14679005
    [Abstract] [Full Text] [Related]

  • 18. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM, Tan C.
    Anticancer Drugs; 2008 Aug 01; 19(7):681-8. PubMed ID: 18594209
    [Abstract] [Full Text] [Related]

  • 19. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
    Faingold D, Marshall JC, Antecka E, Di Cesare S, Odashiro AN, Bakalian S, Fernandes BF, Burnier MN.
    Clin Cancer Res; 2008 Feb 01; 14(3):847-55. PubMed ID: 18245548
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.